An interleukin-6 (IL-6) receptor polymorphism affecting serum levels of IL-6 does not increase the risk of cholangiocarcinoma in primary sclerosing cholangitis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples